NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NeoImmuneTech
Hoffmann-La Roche
AstraZeneca
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of California, San Diego
AstraZeneca
National Cancer Institute (NCI)
AstraZeneca
National Institutes of Health Clinical Center (CC)
Revolution Medicines, Inc.
National Cancer Institute (NCI)
Exelixis
National Institutes of Health Clinical Center (CC)
AstraZeneca
AstraZeneca
University of Kentucky
AstraZeneca
Sanofi
Exelixis
University Health Network, Toronto
University of California, San Diego
Baptist Health South Florida
Verrica Pharmaceuticals Inc.
Pfizer
Hoffmann-La Roche
Numab Therapeutics AG
Regeneron Pharmaceuticals
HiberCell, Inc.
Boston Scientific Corporation
Intensity Therapeutics, Inc.
Alliance for Clinical Trials in Oncology
University of Utah
Sirtex Medical
Baptist Health South Florida
University of California, San Diego
Atara Biotherapeutics
BeiGene
Imunon
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Federation Francophone de Cancerologie Digestive
Advaxis, Inc.
Kyowa Kirin Co., Ltd.
Hoosier Cancer Research Network
Steba Biotech S.A.
MedImmune LLC
Novartis
Eastern Cooperative Oncology Group
University of Kentucky